Article thumbnail
Location of Repository

Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections

By Darlene Miller


Moxifloxacin hydrochloride ophthalmic solution 0.5% (Vigamox®) is the ocular formulation/adaptation of moxifloxacin. Moxifloxacin is a broad spectrum 8-methoxyfluoroquinolone which terminates bacterial growth by binding to DNA gyrase (topoisomerase II) and topoisomerase IV, essential bacterial enzymes involved in the replication, translation, repair and recombination of deoxyribonucleic acid. Affinity for both enzymes improves potency and reduces the probability of selecting resistant bacterial subpopulations. Vigamox is a bactericidal, concentration dependent, anti-infective. It is preservative free, and well tolerated with minimal ocular side effects. It provides increased penetration into ocular tissues and fluids with improved activity against Streptococci and Staphylococci species and moderate to excellent activity against clinically relevant, gram-negative ocular pathogens

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2004). [package insert].
  2. 114:1025; author reply 1026–7.
  3. (2004). A comparison of the fourth-generation fl uoroquinolones gatifl oxacin 0.3% and moxifl oxacin 0.5% in terms of ocular tolerability.
  4. (2005). A comparison of therapeutic regimens containing moxifl oxacin 0.5% ophthalmic solution and gatifl oxacin 0.3% ophthalmic solution for surgical prophylaxis in patients undergoing LASIK or LASEK.
  5. (2002). A critical review of the fl uoroquinolones: focus on respiratory infections.
  6. (2006). A review of new fl uoroquinolones: focus on their use in respiratory tract infections. Treat Respir Med,
  7. (1999). A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on fi ve new respiratory quinolones.
  8. (2005). Absorption of topical moxifl oxacin ophthalmic solution into human aqueous humor.
  9. (2003). Activity of and resistance to moxifl oxacin in Staphylococcus aureus. Antimicrob Agents Chemother,
  10. (1999). Activity of moxifl oxacin against pathogens with decreased susceptibility to ciprofl oxacin.
  11. (2006). Acute endophthalmitis in eyes treated prophylactically with gatifl oxacin and moxifl oxacin.
  12. (2005). Acute-onset endophthalmitis after cataract surgery (2000–2004): incidence, clinical settings, and visual acuity outcomes after treatment.
  13. (2005). An ophthalmologist’s guide to understanding antibiotic susceptibility and minimum inhibitory concentration data.
  14. (2003). An outbreak of Mycobacterium chelonae infection after LASIK.
  15. (2005). Antibiotic susceptibility of preoperative normal conjunctival bacteria.
  16. (2007). Aqueous humor penetration of gatifl oxacin and moxifl oxacin eyedrops given by different methods before cataract surgery.
  17. (2005). Aqueous penetration and biological activity of moxifl oxacin 0.5% ophthalmic solution and gatifl oxacin 0.3% solution in cataract surgery patients.
  18. (2005). ASCRS White Paper: Management of infectious keratitis following laser in situ keratomileusis.
  19. (2007). Bilateral methicillin-resistant Staphylococcus aureus keratitis after photorefractive keratectomy.
  20. (2003). Bilateral methicillin-resistant staphylococcus aureus keratitis in a medical resident following an uneventful bilateral photorefractive keratectomy. Eye Contact Lens,
  21. (2005). Chemother, 43(Suppl B):1–11.Clinical Ophthalmology 2008:2(1) 89 Moxifl oxacin hydrochloride ophthalmic solution
  22. (2004). Ciprofl oxacin and levofl oxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis.
  23. (2007). Clinical response of contact lensassociated fungal keratitis to topical fl uoroquinolone therapy.
  24. (2004). Clinicopathologic case report: scleral buckle associated nontuberculous mycobacterial scleritis. Semin Ophthalmol,
  25. (2004). Comparative in vitro activity of levofl oxacin, ofl oxacin, and ciprofl oxacin against ocular streptococcal isolates.
  26. (2006). Comparative toxicity of fl uoroquinolone antibiotics on corneal cells
  27. (2004). Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fl uoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus.
  28. (2006). Comparison of the biocompatibility of gatifl oxacin 0.3% and moxifl oxacin 0.5%.
  29. (2007). Concentration of moxifl oxacin in serum and human aqueous humor following a single 400 mg oral dose.
  30. (2006). Confocal assessment of the effects of fourth-generation fl uoroquinolones on the cornea. Eye Contact Lens,
  31. (2005). Corneal penetration of fl uoroquinolones: aqueous humor concentrations after topical application of levofl oxacin 0.5% and ofl oxacin 0.3% eyedrops.
  32. (2005). Determination of aqueous and vitreous concentration of moxifl oxacin 0.5% after delivery via a dissolvable corneal collagen shield device.
  33. (2006). Effects of fourth-generation fl uoroquinolones on the ocular surface, epithelium, and wound healing.
  34. (1999). Emerging ciprofl oxacin-resistant Pseudomonas aeruginosa.
  35. (1999). Emerging fl uoroquinolone resistance in bacterial keratitis:a 5-year review.
  36. (2001). Emerging mechanisms of fl uoroquinolone resistance. Emerg Infect Dis,
  37. (2003). Epidemic and sporadic cases of nontuberculous mycobacterial keratitis associated with laser in situ keratomileusis.
  38. (2003). Evaluation and prediction of fl uoroquinolone pharmacodynamics in bacterial keratitis.
  39. (2001). Evaluation of the clinical microbiology profi le of moxifl oxacin. Clin Infect Dis, 32(Suppl 1):S51–63.
  40. (2006). Evidence-based review of moxifl oxacin.
  41. (1999). Expanded activity and utility of the new fl uoroquinolones: a review. Clin Ther, 21:3–40; discussion 1–2.
  42. (2004). Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fl uoroquinolones. Surv Ophthalmol, 49(Suppl 2):S79–83.
  43. (2006). Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase.
  44. (2003). Fluoroquinolones: action and resistance. Curr Top Med Chem,
  45. (2001). Fluoroquinolones: place in ocular therapy.
  46. (2002). Fourth generation fl uoroquinolones: new weapons in the arsenal of ophthalmic antibiotics.
  47. (2006). Fourth-generation fl uoroquinolone penetration into the aqueous humor in humans.
  48. (2006). Fourth-generation fl uoroquinoloneresistant bacterial keratitis after refractive surgery.
  49. (2007). Fourth-generation fl uoroquinoloneresistant mycobacterial keratitis after laser in situ keratomileusis.
  50. (2005). Fourth-generation fl uoroquinolones in the treatment of mycobacterial infectious keratitis after laser-assisted in situ keratomileusis surgery.
  51. (2004). Fourth-generation fl uoroquinolones: new topical agents in the war on ocular bacterial infections. Curr Opin Ophthalmol,
  52. (2003). Gatifl oxacin and moxifl oxacin:an in vitro susceptibility comparison to levofl oxacin, ciprofl oxacin, and ofl oxacin using bacterial keratitis isolates.
  53. (2003). Gatifl oxacin, gemifl oxacin, and moxifl oxacin:the role of 3 newer fl uoroquinolones. Clin Infect Dis,
  54. (1999). Human aqueous and vitreous humour levels of ciprofl oxacin following oral and topical administration.
  55. (2001). Human aqueous humor levels of oral ciprofl oxacin, levofl oxacin, and moxifl oxacin.
  56. (2004). In vitro activities of mutant prevention concentration-targeted concentrations of fl uoroquinolones against Staphylococcus aureus in a pharmacodynamic model.
  57. (2005). In vitro activity of fl uoroquinolones against Mycobacterium abscessus and Mycobacterium chelonae causing infectious keratitis after LASIK in Brazil.
  58. (2007). In vitro activity of fl uoroquinolones against ocular bacterial isolates in Sao Paulo,
  59. (2006). In vitro activity of fl uoroquinolones, vancomycin, and gentamicin against methicillin-resistant Staphylococcus aureus ocular isolates.
  60. (2005). In vitro and in vivo potency of moxifl oxacin and moxifl oxacin ophthalmic solution 0.5%, a new topical fl uoroquinolone. Surv Ophthalmol, 50(Suppl 1):S16–31.
  61. (2003). In vitro antibacterial activity and pharmacodynamics of new quinolones.
  62. (2006). In vitro antifungal activity of the fourth generation fl uoroquinolones against Candida isolates from human ocular infections. Ocul Immunol Infl amm,
  63. (2006). In vitro comparison of the effects of clinically available ophthalmic solutions of gatifl oxacin 0.3% and moxifl oxacin 0.5% on human corneal and conjunctival epithelial cell adhesion and migration and on collagen type IV protein expression.
  64. (2007). In vitro effi cacy and pharmacodynamic indices for antibiotics against coagulase-negative Staphylococcus endophthalmitis isolates.
  65. (2006). In vitro fl uoroquinolone resistance in staphylococcal endophthalmitis isolates. Arch Ophthalmol,
  66. (2001). Increased incidence of corneal perforation after topical fl uoroquinolone treatment for microbial keratitis.
  67. (2003). Infl uence of fl uoroquinolone susceptibility on the therapeutic response of fl uoroquinolone-treated bacterial keratitis. Arch Ophthalmol,
  68. (2006). Intraocular concentrations of gatifl oxacin and moxifl oxacin in the anterior chamber via diffusion through the cornea using collagen shields.
  69. (2003). Maximizing effi cacy and reducing the emergence of resistance.
  70. (2001). Mechanisms of action of antimicrobials: focus on fl uoroquinolones. Clin Infect Dis, 32(Suppl 1):S9–S15.
  71. (2005). Mechanisms of resistance to quinolones. Clin Infect Dis, 41(Suppl 2):S120–6.
  72. (2007). Methicillin-resistant Staphylococcus aureus infectious keratitis following refractive surgery.
  73. (2003). Moxifl oxacin (Avelox): a novel fl uoroquinolone with a broad spectrum of activity. Expert Rev Anti Infect Ther,
  74. (2004). Moxifl oxacin: a review of its use in the management of bacterial infections.
  75. (2004). Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, effl ux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates. Antimicrob Agents Chemother,
  76. (2005). Mutant prevention concentrations of ABT-492, levofl oxacin, moxifl oxacin, and gatifl oxacin against three common respiratory pathogens. Antimicrob Agents Chemother,
  77. (2006). Mycobacterium abscessus endophthalmitis: treatment dilemma and review of the literature.
  78. (2005). Nontuberculous (atypical) mycobacterial keratitis after LASIK: current status and clinical implications.
  79. (2003). Nontuberculous mycobacterial endophthalmitis.
  80. (2005). Ocular penetration of moxifl oxacin 0.5% and gatifl oxacin 0.3% ophthalmic solutions into the aqueous humor following topical administration prior to routine cataract surgery. Curr Med Res Opin,
  81. (2005). Ocular pharmacokinetics of moxifl oxacin after topical treatment of animals and humans. Surv Ophthalmol, 50(Suppl 1):S32–45.
  82. (2006). Ocular pharmacokinetics of moxifl oxacin after topical treatment of animals and humans. Surv Ophthalmol, 51:530; author reply 530–1.
  83. (2005). Ophthalmic infections and their anti-infective challenges. Surv Ophthalmol, 50(Suppl 1):S1–6.
  84. (2005). Overview of the potency of moxifl oxacin ophthalmic solution 0.5% (VIGAMOX). Surv Ophthalmol, 50(Suppl 1):S7–15.
  85. (2005). Penetration of moxifl oxacin into the human aqueous humour after oral administration.
  86. (1999). Penetration of ofl oxacin and ciprofl oxacin in aqueous humor after topical administration. Ophthalmic Surg Lasers,
  87. (2005). Penetration of topically applied gatifl oxacin 0.3%, moxifl oxacin 0.5%, and ciprofl oxacin 0.3% into the aqueous humor.
  88. (2005). Penetration pharmacokinetics of topically administered 0.5% moxifl oxacin ophthalmic solution in human aqueous and vitreous.
  89. (2001). Pharmacokinetics and pharmacodynamics of the new fl uoroquinolones: focus on respiratory infections. Curr Opin Pharmacol,
  90. (2005). Postcataract endophthalmitis caused by Mycobacterium goodii.
  91. (2003). Presumed tubercular serpiginouslike choroiditis: clinical presentations and management.
  92. (2001). Quinolone molecular structure-activity relationships: what we have learned about improving antimicrobial activity. Clin Infect Dis, 33(Suppl 3):S180–6.
  93. (2002). Quinolones: a comprehensive review. Am Fam Physician,
  94. Refract Surg,
  95. (2005). Safety of moxifl oxacin as shown in animal and in vitro studies. Surv Ophthalmol, 50(Suppl 1):S46–54.
  96. (2004). Safety profi le of oral and intravenous moxifl oxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther,
  97. (2003). Selection of moxifl oxacin-resistant Staphylococcus aureus compared with fi ve other fl uoroquinolones.
  98. (2006). Severe corneal toxicity after topical fl uoroquinolone therapy: report of two cases.
  99. (2000). Shifting trends in bacterial keratitis in south Florida and emerging resistance to fl uoroquinolones.
  100. (1996). Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study.
  101. (1994). Structure-activity and structure-side-effect relationships for the quinolone antibacterials.
  102. (2001). Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother,
  103. (2004). The effect of cataract surgery on ocular levels of topical moxifl oxacin.
  104. (2007). The effect of moxifl oxacin and gatifl oxacin on long-term visual outcomes following photorefractive keratectomy.
  105. (2006). The effect of moxifl oxacin on the normal human cornea. Curr Med Res Opin,
  106. (1996). The Endophthalmitis Vitrectomy Study.
  107. (2000). The fl uoroquinolone antibacterials: past, present and future perspectives.
  108. (2006). The worldwide emergence of plasmidmediated quinolone resistance. Lancet Infect Dis,
  109. (1998). Therapeutic advances of new fl uoroquinolones. Expert Opin Investig Drugs,
  110. (2004). Topical antibacterial therapy for mycobacterial keratitis: potential for surgical prophylaxis and treatment. Clin Ther,
  111. (1999). Trends in antibiotic resistance of corneal pathogens: Part I. An Analysis of commonly used antibiotics.
  112. (2007). Vitreal penetration of oral and topical moxifl oxacin in humans.
  113. (2006). Vitreous and aqueous penetration of orally administered moxifl oxacin in humans.
  114. (2006). Vitreous penetration of topical moxifl oxacin and gatifl oxacin in humans.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.